Biotechnology » Biotechnology NAICS: 325414 SIC: 2836|
|Compare:||OTCPK:GLAGD, OTCPK:USRM, OTCPK:NSPX, OTCPK:HSTC, OTCPK:ERGO, OTCPK:PTEO, OTCPK:ENTB, OTCPK:BIEI, OTCPK:LCAR, OTCPK:GOVX, OTCPK:HDVY, OTCPK:TIKRF, OTCPK:VXLLF, OTCPK:BTHE, OTCPK:CLYXF, OTCPK:CAPS, OTCPK:FPMI, OTCPK:CTTC, OTCPK:BPSR, OTCPK:AMAR » details|
Omni Bio Pharmaceutical Inc is a development stage biopharmaceutical company.
Omni Bio Pharmaceutical Inc was incorporated under the name of Across America Financial Services, Inc. On March 31, 2009 Across America Financial Services, Inc. (Across America) completed the acquisition of Apro Bio Pharmaceutical Corporation (Apro Bio) pursuant to the terms of the Agreement of Merger and Plan of Reorganization, as amended (the Merger) among Across America, Apro Bio and Across America Acquisition Corp. (AAAC), a Colorado corporation and a wholly-owned subsidiary of Across America. Under the terms of the Merger, AAAC was merged into Apro Bio, and Apro Bio became a wholly-owned subsidiary of the Company. On May 27, 2009 Across America changed its name to Omni Bio Pharmaceutical, Inc. (Omni). It intends to commercialize a broad patent portfolio licensed from the UCHSC, and a component of these applications involves use of existing FDA approved drugs to treat a variety of bacterial and viral diseases, biohazards and transplant rejection. It is the licensee of filed, but not yet issued, patents related to composition of matter and method of use for an existing FDA approved drug, Alpha 1 Antitrypsin (AAT), for treating organ transplantation, including islet transplantation for the treatment of diabetes and bacterial infections including bacterial pneumonia, tuberculosis and anthrax. It has also licensed an existing patent for the treatment of viral infection including HIV, influenza and potentially the 'bird flu' virus. The Company plans to acquire and develop existing and novel therapies that have the potential to move through clinical trials quickly, shepherd them through the FDA approval processes and advance them through commercialization. This approach is similar to what developed for the drug Minoxodil (trade named Rogaine(r)), which previously had come off its initial patents to treat high blood pressure. It faces intense competition from a range of pharmaceutical, biotechnology and diagnostic companies, as well as academic and research institutions and government agencies. Regulations in the U.S. and other countries would have a significant impact on its research, product development and manufacturing activities and would be a significant factor in the marketing of its products.